Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 115 Urinary Bladder Neoplasms 56 Carcinoma, Non-Small-Cell Lung 53 Cholangiocarcinoma 33 Biliary Tract Neoplasms 32 Neoplasm Metastasis 30 Ovarian Neoplasms 29 Lymphoma, Large B-Cell, Diffuse 27 Breast Neoplasms 25 Neoplasms 24 Lung Neoplasms 24 Carcinoma, Transitional Cell 23 Triple Negative Breast Neoplasms 22 Nasopharyngeal Carcinoma 21 Colorectal Neoplasms 20 Non-Muscle Invasive Bladder Neoplasms 19 Recurrence 17 Fallopian Tube Neoplasms 16 Gallbladder Neoplasms 15 Sarcoma 13 Bile Duct Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Hodgkin Disease 10 Lymphoma 9 Adenocarcinoma 9 Uterine Cervical Neoplasms 8 Stomach Neoplasms 7 Lymphoma, Non-Hodgkin 7 Endometrial Neoplasms 7 Nasopharyngeal Neoplasms 6

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gemcitabine × 1 year × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡